Epigenetics, nervous system tumors, and cancer stem cells

Cancers

Volumn 3, Issue 3, 2011, Pages 3525-3556

  Qureshi, Irfan A ^a   Mehler, Mark F ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Cancer stem cell; Chromatin; Corest; Epigenetic; Glioblastoma multiforme; Nervous system tumor; Non coding RNA; REST

Indexed keywords

ANTINEOPLASTIC AGENT; BIX 01294; DNA METHYLTRANSFERASE 3A; GENOMIC DNA; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL COMMUNICATION; CELL FUNCTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DRUG MECHANISM; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM TUMOR; ONCOGENE; PROTEIN EXPRESSION; REVIEW; RNA EDITING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

EID: 80053214795     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3033525     Document Type: Review

References (208)

1. Mehler, M.F. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Prog. Neurobiol. 2008, 86, 305-341.
2. Rodriguez-Paredes, M.; Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17, 330-339.
3. Mohn, F.; Weber, M.; Rebhan, M.; Roloff, T.C.; Richter, J.; Stadler, M.B.; Bibel, M.; Schubeler, D. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol. Cell 2008, 30, 755-766.
4. Wu, H.; Coskun, V.; Tao, J.; Xie, W.; Ge, W.; Yoshikawa, K.; Li, E.; Zhang, Y.; Sun, Y.E. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 2010, 329, 444-448.
5. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; Rao, A. Conversion of 5-methylcytosine to 5- hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324, 930-935.
6. Koh, K.P.; Yabuuchi, A.; Rao, S.; Huang, Y.; Cunniff, K.; Nardone, J.; Laiho, A.; Tahiliani, M.; Sommer, C.A.; Mostoslavsky, G.; et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8, 200-213.
7. Valinluck, V.; Tsai, H.H.; Rogstad, D.K.; Burdzy, A.; Bird, A.; Sowers, L.C. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 2004, 32, 4100-4108.
8. Jin, S.G.; Kadam, S.; Pfeifer, G.P. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res. 2010, 38, e125.
9. Wu, H.; D'Alessio, A.C.; Ito, S.; Wang, Z.; Cui, K.; Zhao, K.; Sun, Y.E.; Zhang, Y. Genomewide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 2011, 25, 679-684.
10. Ficz, G.; Branco, M.R.; Seisenberger, S.; Santos, F.; Krueger, F.; Hore, T.A.; Marques, C.J.; Andrews, S.; Reik, W. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473, 398-402.
11. Kriaucionis, S.; Heintz, N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324, 929-930.
12. Munzel, M.; Globisch, D.; Bruckl, T.; Wagner, M.; Welzmiller, V.; Michalakis, S.; Muller, M.; Biel, M.; Carell, T. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew. Chem. Int. Ed. Engl. 2010, 49, 5375-5377.
13. Jin, S.G.; Wu, X.; Li, A.X.; Pfeifer, G.P. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res. 2011, 39, 5015-5024.
14. Hirabayashi, Y.; Gotoh, Y. Epigenetic control of neural precursor cell fate during development. Nat. Rev. Neurosci. 2010, 11, 377-388.
15. Juliandi, B.; Abematsu, M.; Nakashima, K. Chromatin remodeling in neural stem cell differentiation. Curr. Opin. Neurobiol. 2010, 20, 408-415.
16. Abrajano, J.J.; Qureshi, I.A.; Gokhan, S.; Zheng, D.; Bergman, A.; Mehler, M.F. REST and CoREST modulate neuronal subtype specification, maturation and maintenance. PLoS one 2009, 4, e7936.
17. Abrajano, J.J.; Qureshi, I.A.; Gokhan, S.; Zheng, D.; Bergman, A.; Mehler, M.F. Differential deployment of REST and CoREST promotes glial subtype specification and oligodendrocyte lineage maturation. PLoS one 2009, 4, e7665.
18. Abrajano, J.J.; Qureshi, I.A.; Gokhan, S.; Molero, A.E.; Zheng, D.; Bergman, A.; Mehler, M.F. Corepressor for element-1-silencing transcription factor preferentially mediates gene networks underlying neural stem cell fate decisions. Proc. Natl. Acad. Sci. USA 2010, 107, 16685-16690.
19. Sun, G.; Alzayady, K.; Stewart, R.; Ye, P.; Yang, S.; Li, W.; Shi, Y. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol. Cell. Biol. 2010, 30, 1997-2005.
20. Hirabayashi, Y.; Suzki, N.; Tsuboi, M.; Endo, T.A.; Toyoda, T.; Shinga, J.; Koseki, H.; Vidal, M.; Gotoh, Y. Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. Neuron 2009, 63, 600-613.
21. Kapranov, P.; St Laurent, G.; Raz, T.; Ozsolak, F.; Reynolds, C.P.; Sorensen, P.H.; Reaman, G.; Milos, P.; Arceci, R.J.; Thompson, J.F.; et al. The majority of total nuclear-encoded nonribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol. 2010, 8, 149.
22. Amaral, P.P.; Dinger, M.E.; Mercer, T.R.; Mattick, J.S. The eukaryotic genome as an RNA machine. Science 2008, 319, 1787-1789.
23. Mehler, M.F.; Mattick, J.S. Non-coding RNAs in the nervous system. J. Physiol. 2006, 575, 333-341.
24. Mattick, J.S.; Amaral, P.P.; Dinger, M.E.; Mercer, T.R.; Mehler, M.F. RNA regulation of epigenetic processes. Bioessays 2009, 31, 51-59.
25. Krol, J.; Loedige, I.; Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11, 597-610.
26. Okazaki, Y.; Furuno, M.; Kasukawa, T.; Adachi, J.; Bono, H.; Kondo, S.; Nikaido, I.; Osato, N.; Saito, R.; Suzuki, H.; et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002, 420, 563-573.
27. Ponjavic, J.; Ponting, C.P.; Lunter, G. Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs. Genome Res 2007, 17, 556-565.
28. Carninci, P.; Kasukawa, T.; Katayama, S.; Gough, J.; Frith, M.C.; Maeda, N.; Oyama, R.; Ravasi, T.; Lenhard, B.; Wells, C.; et al. The transcriptional landscape of the mammalian genome. Science 2005, 309, 1559-1563.
29. Kapranov, P.; Cheng, J.; Dike, S.; Nix, D.A.; Duttagupta, R.; Willingham, A.T.; Stadler, P.F.; Hertel, J.; Hackermuller, J.; Hofacker, I.L.; et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007, 316, 1484-1488.
30. Washietl, S.; Hofacker, I.L.; Lukasser, M.; Huttenhofer, A.; Stadler, P.F. Mapping of conserved RNA secondary structures predicts thousands of functional noncoding RNAs in the human genome. Nat. Biotechnol. 2005, 23, 1383-1390.
31. Pedersen, J.S.; Bejerano, G.; Siepel, A.; Rosenbloom, K.; Lindblad-Toh, K.; Lander, E.S.; Kent, J.; Miller, W.; Haussler, D. Identification and classification of conserved RNA secondary structures in the human genome. PLoS Comput. Biol. 2006, 2, e33.
32. Torarinsson, E.; Yao, Z.; Wiklund, E.D.; Bramsen, J.B.; Hansen, C.; Kjems, J.; Tommerup, N.; Ruzzo, W.L.; Gorodkin, J. Comparative genomics beyond sequence-based alignments: RNA structures in the ENCODE regions. Genome Res. 2008, 18, 242-251.
33. Mattick, J.S.; Makunin, I.V. Small regulatory RNAs in mammals. Hum. Mol. Genet. 2005, 14 Spec No 1, R121-R132.
34. Qureshi, I.A.; Mattick, J.S.; Mehler, M.F. Long non-coding RNAs in nervous system function and disease. Brain Res. 2010, 1338, 20-35.
35. Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: Insights into functions. Nat. Rev. Genet. 2009, 10, 155-159.
36. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; Argani, P.; Rinn, J.L.; et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464, 1071-1076.
37. Shi, Y.; Zhao, X.; Hsieh, J.; Wichterle, H.; Impey, S.; Banerjee, S.; Neveu, P.; Kosik, K.S. MicroRNA regulation of neural stem cells and neurogenesis. J. Neurosci. 2010, 30, 14931-14936.
38. Cheng, L.C.; Pastrana, E.; Tavazoie, M.; Doetsch, F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 2009, 12, 399-408.
39. Dugas, J.C.; Cuellar, T.L.; Scholze, A.; Ason, B.; Ibrahim, A.; Emery, B.; Zamanian, J.L.; Foo, L.C.; McManus, M.T.; Barres, B.A. Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination. Neuron 2010, 65, 597-611.
40. Zhao, X.; He, X.; Han, X.; Yu, Y.; Ye, F.; Chen, Y.; Hoang, T.; Xu, X.; Mi, Q.S.; Xin, M.; et al. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron 2010, 65, 612-626.
41. Mercer, T.R.; Qureshi, I.A.; Gokhan, S.; Dinger, M.E.; Li, G.; Mattick, J.S.; Mehler, M.F. Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci. 2010, 11, 14.
42. Tochitani, S.; Hayashizaki, Y. Nkx2.2 antisense RNA overexpression enhanced oligodendrocytic differentiation. Biochem. Biophys. Res. Commun. 2008, 372, 691-696.
43. Guttman, M.; Amit, I.; Garber, M.; French, C.; Lin, M.F.; Feldser, D.; Huarte, M.; Zuk, O.; Carey, B.W.; Cassady, J.P.; et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009, 458, 223-227.
44. Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 2010, 79, 321-349.
45. St Laurent, G., 3rd; Savva, Y.A.; Reenan, R. Enhancing non-coding RNA information content with ADAR editing. Neurosci. Lett. 2009, 466, 89-98.
46. Jacobs, M.M.; Fogg, R.L.; Emeson, R.B.; Stanwood, G.D. ADAR1 and ADAR2 expression and editing activity during forebrain development. Dev. Neurosci. 2009, 31, 223-237.
47. Melcher, T.; Maas, S.; Herb, A.; Sprengel, R.; Higuchi, M.; Seeburg, P.H. RED2, a brain-specific member of the RNA-specific adenosine deaminase family. J. Biol. Chem. 1996, 271, 31795-31798.
48. Mehler, M.F.; Mattick, J.S. Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. Physiol. Rev. 2007, 87, 799-823.
49. Blow, M.; Futreal, P.A.; Wooster, R.; Stratton, M.R. A survey of RNA editing in human brain. Genome Res. 2004, 14, 2379-2387.
50. Li, J.B.; Levanon, E.Y.; Yoon, J.K.; Aach, J.; Xie, B.; Leproust, E.; Zhang, K.; Gao, Y.; Church, G.M. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science 2009, 324, 1210-1213.
51. Athanasiadis, A.; Rich, A.; Maas, S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004, 2, e391.
52. Hundley, H.A.; Bass, B.L. ADAR editing in double-stranded UTRs and other noncoding RNA sequences. Trends Biochem. Sci. 2010, 35, 377-383.
53. Kawahara, Y.; Megraw, M.; Kreider, E.; Iizasa, H.; Valente, L.; Hatzigeorgiou, A.G.; Nishikura, K. Frequency and fate of microRNA editing in human brain. Nucleic Acids Res. 2008, 36, 5270-5280.
54. Osenberg, S.; Paz Yaacov, N.; Safran, M.; Moshkovitz, S.; Shtrichman, R.; Sherf, O.; Jacob-Hirsch, J.; Keshet, G.; Amariglio, N.; Itskovitz-Eldor, J.; et al. Alu sequences in undifferentiated human embryonic stem cells display high levels of A-to-I RNA editing. PLoS one 2010, 5, e11173.
55. Whitney, N.P.; Peng, H.; Erdmann, N.B.; Tian, C.; Monaghan, D.T.; Zheng, J.C. Calciumpermeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons. FASEB J. 2008, 22, 2888-2900.
56. Qureshi, I.A.; Mehler, M.F. Regulation of non-coding RNA networks in the nervous system-- what's the REST of the story? Neurosci. Lett. 2009, 466, 73-80.
57. Nunez, E.; Fu, X.D.; Rosenfeld, M.G. Nuclear organization in the 3D space of the nucleus - cause or consequence? Curr. Opin. Genet. Dev. 2009, 19, 424-436.
58. Zhao, R.; Bodnar, M.S.; Spector, D.L. Nuclear neighborhoods and gene expression. Curr. Opin. Genet. Dev. 2009, 19, 172-179.
59. Lanctot, C.; Cheutin, T.; Cremer, M.; Cavalli, G.; Cremer, T. Dynamic genome architecture in the nuclear space: regulation of gene expression in three dimensions. Nat. Rev. Genet. 2007, 8, 104-115.
60. Joffe, B.; Leonhardt, H.; Solovei, I. Differentiation and large scale spatial organization of the genome. Curr. Opin. Genet. Dev. 2010, 20, 562-569.
61. Qureshi, I.A.; Mehler, M.F. Impact of nuclear organization and dynamics on epigenetic regulation in the central nervous system: implications for neurological disease states. Ann. N.Y. Acad. Sci. 2010, 1204, E20-E37.
62. Misteli, T. Higher-order genome organization in human disease. Cold Spring Harb. Perspect. Biol. 2010, doi:10.1101/cshperspect.a000794.
63. Williams, R.R.; Azuara, V.; Perry, P.; Sauer, S.; Dvorkina, M.; Jorgensen, H.; Roix, J.; McQueen, P.; Misteli, T.; Merkenschlager, M.; et al. Neural induction promotes large-scale chromatin reorganisation of the Mash1 locus. J. Cell Sci. 2006, 119, 132-140.
64. Nielsen, J.A.; Hudson, L.D.; Armstrong, R.C. Nuclear organization in differentiating oligodendrocytes. J. Cell Sci. 2002, 115, 4071-4079.
65. Lin, S.T.; Fu, Y.H. miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination. Dis. Model. Mech. 2009, 2, 178-188.
66. Lin, S.T.; Ptacek, L.J.; Fu, Y.H. Adult-onset autosomal dominant leukodystrophy: linking nuclear envelope to myelin. J. Neurosci. 2011, 31, 1163-1166.
67. Manuyakorn, A.; Paulus, R.; Farrell, J.; Dawson, N.A.; Tze, S.; Cheung-Lau, G.; Hines, O.J.; Reber, H.; Seligson, D.B.; Horvath, S.; et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J. Clin. Oncol. 2010, 28, 1358-1365.
68. Elsheikh, S.E.; Green, A.R.; Rakha, E.A.; Powe, D.G.; Ahmed, R.A.; Collins, H.M.; Soria, D.; Garibaldi, J.M.; Paish, C.E.; Ammar, A.A.; et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009, 69, 3802-3809.
69. Seligson, D.B.; Horvath, S.; McBrian, M.A.; Mah, V.; Yu, H.; Tze, S.; Wang, Q.; Chia, D.; Goodglick, L.; Kurdistani, S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174, 1619-1628.
70. Kondo, Y.; Shen, L.; Cheng, A.S.; Ahmed, S.; Boumber, Y.; Charo, C.; Yamochi, T.; Urano, T.; Furukawa, K.; Kwabi-Addo, B.; et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40, 741-750.
71. Guil, S.; Esteller, M. DNA methylomes, histone codes and miRNAs: Tying it all together. Int. J. Biochem. Cell Biol. 2009, 41, 87-95.
72. Dinger, M.E.; Amaral, P.P.; Mercer, T.R.; Pang, K.C.; Bruce, S.J.; Gardiner, B.B.; Askarian-Amiri, M.E.; Ru, K.; Solda, G.; Simons, C.; et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008, 18, 1433-1445.
73. Sheik Mohamed, J.; Gaughwin, P.M.; Lim, B.; Robson, P.; Lipovich, L. Conserved long Nonco ing RNAs transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells. RNA 2010, 16, 324-337.
74. Hawkins, P.G.; Morris, K.V. Transcriptional regulation of Oct4 by a long non-coding RNA antisense to Oct4-pseudogene 5. Transcription 2010, 1, 165-175.
75. Huarte, M.; Guttman, M.; Feldser, D.; Garber, M.; Koziol, M.J.; Kenzelmann-Broz, D.; Khalil, A.M.; Zuk, O.; Amit, I.; Rabani, M.; et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010, 142, 409-419.
76. Huarte, M.; Rinn, J.L. Large non-coding RNAs: Missing links in cancer? Hum. Mol. Genet. 2010, 19, R152-R161.
77. Martinez, R.; Esteller, M. The DNA methylome of glioblastoma multiforme. Neurobiol. Dis. 2010, 39, 40-46.
78. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807-1812.
79. Rajendran, G.; Shanmuganandam, K.; Bendre, A.; Mujumdar, D.; Goel, A.; Shiras, A. Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. J. Neuro-Oncol. 2011, 104, 483-494.
80. Lucio-Eterovic, A.K.; Cortez, M.A.; Valera, E.T.; Motta, F.J.; Queiroz, R.G.; Machado, H.R.; Carlotti, C.G., Jr.; Neder, L.; Scrideli, C.A.; Tone, L.G. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: Class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008, 8, 243.
81. Hayry, V.; Tanner, M.; Blom, T.; Tynninen, O.; Roselli, A.; Ollikainen, M.; Sariola, H.; Wartiovaara, K.; Nupponen, N.N. Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathol. 2008, 116, 97-102.
82. Shah, N.; Lin, B.; Sibenaller, Z.; Ryken, T.; Lee, H.; Yoon, J.G.; Rostad, S.; Foltz, G. Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM. PLoS one 2011, 6, e16146.
83. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061-1068.
84. Gonzalez-Gomez, P.; Bello, M.J.; Arjona, D.; Lomas, J.; Alonso, M.E.; De Campos, J.M.; Vaquero, J.; Isla, A.; Gutierrez, M.; Rey, J.A. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int. J. Oncol. 2003, 22, 601-608.
85. Yu, J.; Zhang, H.; Gu, J.; Lin, S.; Li, J.; Lu, W.; Wang, Y.; Zhu, J. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004, 4, 65.
86. Piperi, C.; Themistocleous, M.S.; Papavassiliou, G.A.; Farmaki, E.; Levidou, G.; Korkolopoulou, P.; Adamopoulos, C.; Papavassiliou, A.G. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol. Med. 2010, 16, 1-9.
87. Laffaire, J.; Everhard, S.; Idbaih, A.; Criniere, E.; Marie, Y.; de Reynies, A.; Schiappa, R.; Mokhtari, K.; Hoang-Xuan, K.; Sanson, M.; et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol. 2011, 13, 84-98.
88. Fowler, A.; Thomson, D.; Giles, K.; Maleki, S.; Mreich, E.; Wheeler, H.; Leedman, P.; Biggs, M.; Cook, R.; Little, N.; et al. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur. J. Cancer 2011, 47, 953-963.
89. Papagiannakopoulos, T.; Shapiro, A.; Kosik, K.S. MicroRNA-21 targets a network of key tumorsuppressive pathways in glioblastoma cells. Cancer Res. 2008, 68, 8164-8172.
90. Dong, H.; Siu, H.; Luo, L.; Fang, X.; Jin, L.; Xiong, M. Investigation gene and microRNA expression in glioblastoma. BMC Genomics 2010, 11 (Suppl. 3), S16.
91. Korneev, S.A.; Korneeva, E.I.; Lagarkova, M.A.; Kiselev, S.L.; Critchley, G.; O'Shea, M. Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells. RNA 2008, 14, 2030-2037.
92. Broholm, H.; Rubin, I.; Kruse, A.; Braendstrup, O.; Schmidt, K.; Skriver, E.B.; Lauritzen, M. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin. Neuropathol. 2003, 22, 273-281.
93. Grinchuk, O.V.; Jenjaroenpun, P.; Orlov, Y.L.; Zhou, J.; Kuznetsov, V.A. Integrative analysis of the human cis-antisense gene pairs, miRNAs and their transcription regulation patterns. Nucleic Acids Res 2010, 38, 534-547.
94. Paz, N.; Levanon, E.Y.; Amariglio, N.; Heimberger, A.B.; Ram, Z.; Constantini, S.; Barbash, Z.S.; Adamsky, K.; Safran, M.; Hirschberg, A.; et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007, 17, 1586-1595.
95. Maas, S.; Patt, S.; Schrey, M.; Rich, A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. USA 2001, 98, 14687-14692.
96. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D.H.; Gainche, L.; Sena-Esteves, M.; Curry, W.T., Jr.; Carter, B.S.; Krichevsky, A.M.; Breakefield, X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10, 1470-1476.
97. Balaj, L.; Lessard, R.; Dai, L.; Cho, Y.J.; Pomeroy, S.L.; Breakefield, X.O.; Skog, J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2011, 2, 180.
98. Dong, S.M.; Pang, J.C.; Poon, W.S.; Hu, J.; To, K.F.; Chang, A.R.; Ng, H.K. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J. Neuropathol. Exp. Neurol. 2001, 60, 808-816.
99. Alonso, M.E.; Bello, M.J.; Gonzalez-Gomez, P.; Arjona, D.; Lomas, J.; de Campos, J.M.; Isla, A.; Sarasa, J.L.; Rey, J.A. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet. Cytogenet. 2003, 144, 134-142.
100. Cogdell, D.; Chung, W.; Liu, Y.; McDonald, J.M.; Aldape, K.; Issa, J.P.; Fuller, G.N.; Zhang, W. Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chin. J. Cancer 2011, 30, 247-253.
101. Pang, J.C.; Li, K.K.; Lau, K.M.; Ng, Y.L.; Wong, J.; Chung, N.Y.; Li, H.M.; Chui, Y.L.; Lui, V.W.; Chen, Z.P.; et al. KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol. 2010, 20, 1021-1032.
102. Parsons, D.W.; Li, M.; Zhang, X.; Jones, S.; Leary, R.J.; Lin, J.C.; Boca, S.M.; Carter, H.; Samayoa, J.; Bettegowda, C.; et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331, 435-439.
103. Northcott, P.A.; Nakahara, Y.; Wu, X.; Feuk, L.; Ellison, D.W.; Croul, S.; Mack, S.; Kongkham, P.N.; Peacock, J.; Dubuc, A.; et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat. Genet. 2009, 41, 465-472.
104. Lawinger, P.; Venugopal, R.; Guo, Z.S.; Immaneni, A.; Sengupta, D.; Lu, W.; Rastelli, L.; Marin Dias Carneiro, A.; Levin, V.; Fuller, G.N.; et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat. Med. 2000, 6, 826-831.
105. Fuller, G.N.; Su, X.; Price, R.E.; Cohen, Z.R.; Lang, F.F.; Sawaya, R.; Majumder, S. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol. Cancer Ther. 2005, 4, 343-349.
106. Blom, T.; Tynninen, O.; Puputti, M.; Halonen, M.; Paetau, A.; Haapasalo, H.; Tanner, M.; Nupponen, N.N. Molecular genetic analysis of the REST/NRSF gene in nervous system tumors. Acta Neuropathol. 2006, 112, 483-490.
107. Su, X.; Gopalakrishnan, V.; Stearns, D.; Aldape, K.; Lang, F.F.; Fuller, G.; Snyder, E.; Eberhart, C.G.; Majumder, S. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol. Cell. Biol. 2006, 26, 1666-1678.
108. Qureshi, I.A.; Gokhan, S.; Mehler, M.F. REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions. Cell Cycle 2010, 9, 4477-4486.
109. Uziel, T.; Karginov, F.V.; Xie, S.; Parker, J.S.; Wang, Y.D.; Gajjar, A.; He, L.; Ellison, D.; Gilbertson, R.J.; Hannon, G.; et al. The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc. Natl. Acad. Sci. USA 2009, 106, 2812-2817.
110. Northcott, P.A.; Fernandez, L.A.; Hagan, J.P.; Ellison, D.W.; Grajkowska, W.; Gillespie, Y.; Grundy, R.; Van Meter, T.; Rutka, J.T.; Croce, C.M.; et al. The miR-17/92 polycistron is upregulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehogtreated cerebellar neural precursors. Cancer Res. 2009, 69, 3249-3255.
111. Cho, Y.J.; Tsherniak, A.; Tamayo, P.; Santagata, S.; Ligon, A.; Greulich, H.; Berhoukim, R.; Amani, V.; Goumnerova, L.; Eberhart, C.G.; et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 2011, 29, 1424-1430.
112. Buckley, P.G.; Das, S.; Bryan, K.; Watters, K.M.; Alcock, L.; Koster, J.; Versteeg, R.; Stallings, R.L. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int. J. Cancer 2011, 128, 2296-2305.
113. Yang, Q.W.; Liu, S.; Tian, Y.; Salwen, H.R.; Chlenski, A.; Weinstein, J.; Cohn, S.L. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 2003, 63, 6299-6310.
114. van Noesel, M.M.; van Bezouw, S.; Salomons, G.S.; Voute, P.A.; Pieters, R.; Baylin, S.B.; Herman, J.G.; Versteeg, R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 2002, 62, 2157-2161.
115. Eggert, A.; Grotzer, M.A.; Zuzak, T.J.; Wiewrodt, B.R.; Ho, R.; Ikegaki, N.; Brodeur, G.M. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 2001, 61, 1314-1319.
116. Teitz, T.; Wei, T.; Valentine, M.B.; Vanin, E.F.; Grenet, J.; Valentine, V.A.; Behm, F.G.; Look, A.T.; Lahti, J.M.; Kidd, V.J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000, 6, 529-535.
117. Shahi, M.H.; Schiapparelli, P.; Afzal, M.; Sinha, S.; Rey, J.A.; Castresana, J.S. Expression and epigenetic modulation of sonic hedgehog-GLI1 pathway genes in neuroblastoma cell lines and tumors. Tumour Biol. 2011, 32, 113-127.
118. Yang, Q.; Tian, Y.; Ostler, K.R.; Chlenski, A.; Guerrero, L.J.; Salwen, H.R.; Godley, L.A.; Cohn, S.L. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer 2010, 10, 286.
119. Caren, H.; Djos, A.; Nethander, M.; Sjoberg, R.M.; Kogner, P.; Enstrom, C.; Nilsson, S.; Martinsson, T. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer 2011, 11, 66.
120. Gonzalez-Gomez, P.; Bello, M.J.; Lomas, J.; Arjona, D.; Alonso, M.E.; Aminoso, C.; Lopez-Marin, I.; Anselmo, N.P.; Sarasa, J.L.; Gutierrez, M.; et al. Aberrant methylation of multiple genes in neuroblastic tumours. relationship with MYCN amplification and allelic status at 1p. Eur. J. Cancer 2003, 39, 1478-1485.
121. Grau, E.; Martinez, F.; Orellana, C.; Canete, A.; Yanez, Y.; Oltra, S.; Noguera, R.; Hernandez, M.; Bermudez, J.D.; Castel, V. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol. Carcinog. 2011, 50, 153-162.
122. Hoebeeck, J.; Michels, E.; Pattyn, F.; Combaret, V.; Vermeulen, J.; Yigit, N.; Hoyoux, C.; Laureys, G.; De Paepe, A.; Speleman, F.; et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett. 2009, 273, 336-346.
123. Abe, M.; Ohira, M.; Kaneda, A.; Yagi, Y.; Yamamoto, S.; Kitano, Y.; Takato, T.; Nakagawara, A.; Ushijima, T. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005, 65, 828-834.
124. Abe, M.; Westermann, F.; Nakagawara, A.; Takato, T.; Schwab, M.; Ushijima, T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett. 2007, 247, 253-258.
125. Abe, M.; Watanabe, N.; McDonell, N.; Takato, T.; Ohira, M.; Nakagawara, A.; Ushijima, T. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008, 74, 50-60.
126. Nishimura, E.; Sasaki, K.; Maruyama, K.; Tsukada, T.; Yamaguchi, K. Decrease in neuron-restrictive silencer factor (NRSF) mRNA levels during differentiation of cultured neuroblastoma cells. Neurosci. Lett. 1996, 211, 101-104.
127. Palm, K.; Metsis, M.; Timmusk, T. Neuron-specific splicing of zinc finger transcription factor REST/NRSF/XBR is frequent in neuroblastomas and conserved in human, mouse and rat. Brain Res. Mol. Brain Res. 1999, 72, 30-39.
128. Lee, J.H.; Chai, Y.G.; Hersh, L.B. Expression patterns of mouse repressor element-1 silencing transcription factor 4 (REST4) and its possible function in neuroblastoma. J. Mol. Neurosci. 2000, 15, 205-214.
129. Chen, H.; Shalom-Feuerstein, R.; Riley, J.; Zhang, S.D.; Tucci, P.; Agostini, M.; Aberdam, D.; Knight, R.A.; Genchi, G.; Nicotera, P.; et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem. Biophys. Res. Commun. 2010, 394, 921-927.
130. Laneve, P.; Di Marcotullio, L.; Gioia, U.; Fiori, M.E.; Ferretti, E.; Gulino, A.; Bozzoni, I.; Caffarelli, E. The interplay between microRNAs and the neurotrophin receptor tropomyosinrelated kinase C controls proliferation of human neuroblastoma cells. Proc. Natl. Acad. Sci. USA 2007, 104, 7957-7962.
131. Laneve, P.; Gioia, U.; Andriotto, A.; Moretti, F.; Bozzoni, I.; Caffarelli, E. A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation. Nucleic Acids Res. 2010, 38, 6895-6905.
132. Fontana, L.; Fiori, M.E.; Albini, S.; Cifaldi, L.; Giovinazzi, S.; Forloni, M.; Boldrini, R.; Donfrancesco, A.; Federici, V.; Giacomini, P.; et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS one 2008, 3, e2236.
133. Michalowski, M.B.; de Fraipont, F.; Michelland, S.; Entz-Werle, N.; Grill, J.; Pasquier, B.; Favrot, M.C.; Plantaz, D. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet. Cytogenet. 2006, 166, 74-81.
134. Hamilton, D.W.; Lusher, M.E.; Lindsey, J.C.; Ellison, D.W.; Clifford, S.C. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett. 2005, 227, 75-81
135. Rousseau, E.; Ruchoux, M.M.; Scaravilli, F.; Chapon, F.; Vinchon, M.; De Smet, C.; Godfraind, C.; Vikkula, M. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol. Appl. Neurobiol. 2003, 29, 574-583.
136. Alonso, M.E.; Bello, M.J.; Gonzalez-Gomez, P.; Arjona, D.; de Campos, J.M.; Gutierrez, M.; Rey, J.A. Aberrant CpG island methylation of multiple genes in ependymal tumors. J. Neurooncol. 2004, 67, 159-165.
137. Xie, H.; Wang, M.; Bonaldo Mde, F.; Rajaram, V.; Stellpflug, W.; Smith, C.; Arndt, K.; Goldman, S.; Tomita, T.; Soares, M.B. Epigenomic analysis of Alu repeats in human ependymomas. Proc Natl Acad Sci USA 2010, 107, 6952-6957.
138. Roberts, C.W.; Galusha, S.A.; McMenamin, M.E.; Fletcher, C.D.; Orkin, S.H. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl. Acad. Sci. USA 2000, 97, 13796-13800.
139. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
140. Dirks, P.B. Brain tumor stem cells: The cancer stem cell hypothesis writ large. Mol. Oncol. 2010, 4, 420-430.
141. Dimov, I.; Tasic Dimov, D.; Conic, I.; Stefanovic, V. Glioblastoma multiforme stem cells. ScientificWorldJournal 2011, 11, 930-958.
142. Prestegarden, L.; Enger, P.O. Cancer stem cells in the central nervous system-A critical review. Cancer Res. 2010, 70, 8255-8258.
143. Notta, F.; Mullighan, C.G.; Wang, J.C.; Poeppl, A.; Doulatov, S.; Phillips, L.A.; Ma, J.; Minden, M.D.; Downing, J.R.; Dick, J.E. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469, 362-367.
144. Anderson, K.; Lutz, C.; van Delft, F.W.; Bateman, C.M.; Guo, Y.; Colman, S.M.; Kempski, H.; Moorman, A.V.; Titley, I.; Swansbury, J.; et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469, 356-361.
145. Yi, J.M.; Tsai, H.C.; Glockner, S.C.; Lin, S.; Ohm, J.E.; Easwaran, H.; James, C.D.; Costello, J.F.; Riggins, G.; Eberhart, C.G.; et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008, 68, 8094-8103.
146. Tabu, K.; Sasai, K.; Kimura, T.; Wang, L.; Aoyanagi, E.; Kohsaka, S.; Tanino, M.; Nishihara, H.; Tanaka, S. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res. 2008, 18, 1037-1046.
147. Capper, D.; Gaiser, T.; Hartmann, C.; Habel, A.; Mueller, W.; Herold-Mende, C.; von Deimling, A.; Siegelin, M.D. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit downregulation of caspase-8 by promoter methylation. Acta Neuropathol. 2009, 117, 445-456. Cancers 2011, 3 3553
148. Lee, J.; Son, M.J.; Woolard, K.; Donin, N.M.; Li, A.; Cheng, C.H.; Kotliarova, S.; Kotliarov, Y.; Walling, J.; Ahn, S.; et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008, 13, 69-80.
149. Gal, H.; Pandi, G.; Kanner, A.A.; Ram, Z.; Lithwick-Yanai, G.; Amariglio, N.; Rechavi, G.; Givol, D. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem. Biophys. Res. Commun. 2008, 376, 86-90.
150. Cortez, M.A.; Nicoloso, M.S.; Shimizu, M.; Rossi, S.; Gopisetty, G.; Molina, J.R.; Carlotti, C., Jr.; Tirapelli, D.; Neder, L.; Brassesco, M.S.; et al. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 2010, 49, 981-990.
151. Silber, J.; Lim, D.A.; Petritsch, C.; Persson, A.I.; Maunakea, A.K.; Yu, M.; Vandenberg, S.R.; Ginzinger, D.G.; James, C.D.; Costello, J.F.; et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6, 14.
152. Schiapparelli, P.; Enguita-German, M.; Balbuena, J.; Rey, J.A.; Lazcoz, P.; Castresana, J.S. Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines. Oncol. Rep. 2010, 24, 1355-1362.
153. Garzia, L.; Andolfo, I.; Cusanelli, E.; Marino, N.; Petrosino, G.; De Martino, D.; Esposito, V.; Galeone, A.; Navas, L.; Esposito, S.; et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS one 2009, 4, e4998.
154. Visvader, J.E. Cells of origin in cancer. Nature 2011, 469, 314-322.
155. Yang, Z.J.; Ellis, T.; Markant, S.L.; Read, T.A.; Kessler, J.D.; Bourboulas, M.; Schuller, U.; Machold, R.; Fishell, G.; Rowitch, D.H.; et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008, 14, 135-145.
156. Scaffidi, P.; Misteli, T. Cancer epigenetics: From disruption of differentiation programs to the emergence of cancer stem cells. Cold Spring Harb. Symp. Quant. Biol. 2010, doi:10.1101/sqb.2010.75.007.
157. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
158. Gates, K.P.; Mentzer, L.; Karlstrom, R.O.; Sirotkin, H.I. The transcriptional repressor REST/NRSF modulates hedgehog signaling. Dev. Biol. 2010, 340, 293-305.
159. Nishihara, S.; Tsuda, L.; Ogura, T. The canonical Wnt pathway directly regulates NRSF/REST expression in chick spinal cord. Biochem. Biophys. Res. Commun. 2003, 311, 55-63.
160. Kohyama, J.; Sanosaka, T.; Tokunaga, A.; Takatsuka, E.; Tsujimura, K.; Okano, H.; Nakashima, K. BMP-induced REST regulates the establishment and maintenance of astrocytic identity. J. Cell Biol. 2010, 189, 159-170.
161. Longworth, M.S.; Dyson, N.J. pRb, a local chromatin organizer with global possibilities. Chromosoma 2010, 119, 1-11.
162. Schoeftner, S.; Blasco, M.A. Chromatin regulation and non-coding RNAs at mammalian telomeres. Semin. Cell Dev. Biol. 2010, 21, 186-193.
163. Rahman, R.; Osteso-Ibanez, T.; Hirst, R.A.; Levesley, J.; Kilday, J.P.; Quinn, S.; Peet, A.; O'Callaghan, C.; Coyle, B.; Grundy, R.G. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. Mol. Cancer Ther. 2010, 9, 2568-2581.
164. Caslini, C. Transcriptional regulation of telomeric non-coding RNA: Implications on telomere biology, replicative senescence and cancer. RNA Biol. 2010, 7, 18-22.
165. Turunen, M.P.; Yla-Herttuala, S. Epigenetic regulation of key vascular genes and growth factors. Cardiovasc. Res. 2011, 90, 441-446.
166. Lu, C.; Han, H.D.; Mangala, L.S.; Ali-Fehmi, R.; Newton, C.S.; Ozbun, L.; Armaiz-Pena, G.N.; Hu, W.; Stone, R.L.; Munkarah, A.; et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010, 18, 185-197.
167. Sasayama, T.; Nishihara, M.; Kondoh, T.; Hosoda, K.; Kohmura, E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int. J. Cancer 2009, 125, 1407-1413.
168. Fowler, A.; Thomson, D.; Giles, K.; Maleki, S.; Mreich, E.; Wheeler, H.; Leedman, P.; Biggs, M.; Cook, R.; Little, N.; et al. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur. J. Cancer 2011, 47, 953-963.
169. Yang, Z.; Zhou, L.; Wu, L.M.; Lai, M.C.; Xie, H.Y.; Zhang, F.; Zheng, S.S. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann. Surg. Oncol. 2011, 18, 1243-1250.
170. Wang, B.; Moya, N.; Niessen, S.; Hoover, H.; Mihaylova, M.M.; Shaw, R.J.; Yates, J.R., 3rd; Fischer, W.H.; Thomas, J.B.; Montminy, M. A hormone-dependent module regulating energy balance. Cell 2011, 145, 596-606.
171. Mihaylova, M.M.; Vasquez, D.S.; Ravnskjaer, K.; Denechaud, P.D.; Yu, R.T.; Alvarez, J.G.; Downes, M.; Evans, R.M.; Montminy, M.; Shaw, R.J. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 2011, 145, 607-621.
172. Villagra, A.; Sotomayor, E.M.; Seto, E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 2010, 29, 157-173.
173. Gilbertson, R.J.; Rich, J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 2007, 7, 733-736.
174. Fan, X.; Khaki, L.; Zhu, T.S.; Soules, M.E.; Talsma, C.E.; Gul, N.; Koh, C.; Zhang, J.; Li, Y.M.; Maciaczyk, J.; et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28, 5-16.
175. Borggrefe, T.; Oswald, F. The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell. Mol. Life Sci. 2009, 66, 1631-1646.
176. Lathia, J.D.; Gallagher, J.; Heddleston, J.M.; Wang, J.; Eyler, C.E.; Macswords, J.; Wu, Q.; Vasanji, A.; McLendon, R.E.; Hjelmeland, A.B.; et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6, 421-432.
177. Sun, Y.M.; Cooper, M.; Finch, S.; Lin, H.H.; Chen, Z.F.; Williams, B.P.; Buckley, N.J. Rest-mediat d regulation of extracellular matrix is crucial for neural development. PLoS one 2008, 3, e3656.
178. Lehtinen, M.K.; Zappaterra, M.W.; Chen, X.; Yang, Y.J.; Hill, A.D.; Lun, M.; Maynard, T.; Gonzalez, D.; Kim, S.; Ye, P.; et al. The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron 2011, 69, 893-905.
179. Berteaux, N.; Aptel, N.; Cathala, G.; Genton, C.; Coll, J.; Daccache, A.; Spruyt, N.; Hondermarck, H.; Dugimont, T.; Curgy, J.J.; et al. A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol. Cell. Biol. 2008, 28, 6731-6745.
180. Chao, W.; D'Amore, P.A. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008, 19, 111-120.
181. Smalheiser, N.R. Do neural cells communicate with endothelial cells via secretory exosomes and microvesicles? Cardiovasc. Psychiatry Neurol. 2009, 2009, 383086.
182. Papait, R.; Magrassi, L.; Rigamonti, D.; Cattaneo, E. Temozolomide and carmustine cause largescale heterochromatin reorganization in glioma cells. Biochem. Biophys. Res. Commun. 2009, 379, 434-439.
183. Csoka, A.B.; Szyf, M. Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology. Med. Hypotheses 2009, 73, 770-780.
184. Nagarajan, R.P.; Costello, J.F. Epigenetic mechanisms in glioblastoma multiforme. Semin. Cancer Biol. 2009, 19, 188-197.
185. Greiner, D.; Bonaldi, T.; Eskeland, R.; Roemer, E.; Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 2005, 1, 143-145.
186. Kubicek, S.; O'Sullivan, R.J.; August, E.M.; Hickey, E.R.; Zhang, Q.; Teodoro, M.L.; Rea, S.; Mechtler, K.; Kowalski, J.A.; Homon, C.A.; et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 2007, 25, 473-481.
187. Lee, M.G.; Wynder, C.; Schmidt, D.M.; McCafferty, D.G.; Shiekhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 2006, 13, 563-567.
188. Schmidt, D.M.; McCafferty, D.G. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007, 46, 4408-4416.
189. Culhane, J.C.; Wang, D.; Yen, P.M.; Cole, P.A. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J. Am. Chem. Soc. 2010, 132, 3164-3176.
190. Tan, J.; Yang, X.; Zhuang, L.; Jiang, X.; Chen, W.; Lee, P.L.; Karuturi, R.K.; Tan, P.B.; Liu, E.T.; Yu, Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21, 1050-1063.
191. Tariq, M.; Nussbaumer, U.; Chen, Y.; Beisel, C.; Paro, R. Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression. Proc. Natl. Acad. Sci. USA 2009, 106, 1157-1162.
192. Rigamonti, D.; Mutti, C.; Zuccato, C.; Cattaneo, E.; Contini, A. Turning REST/NRSF dysfunction in Huntington's disease into a pharmaceutical target. Curr. Pharm. Des. 2009, 15, 3958-3967.
193. Leone, S.; Mutti, C.; Kazantsev, A.; Sturlese, M.; Moro, S.; Cattaneo, E.; Rigamonti, D.; Contini, A. SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorg. Med. Chem. 2008, 16, 5695-5703.
194. Rigamonti, D.; Bolognini, D.; Mutti, C.; Zuccato, C.; Tartari, M.; Sola, F.; Valenza, M.; Kazantsev, A.G.; Cattaneo, E. Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J. Biol. Chem. 2007, 282, 24554-24562.
195. Benjamin, H.; Lebanony, D.; Rosenwald, S.; Cohen, L.; Gibori, H.; Barabash, N.; Ashkenazi, K.; Goren, E.; Meiri, E.; Morgenstern, S.; et al. A diagnostic assay based on microrna expression accurately identifies malignant pleural mesothelioma. J. Mol. Diagn. 2010, 12, 771-779.
196. Meiri, E.; Levy, A.; Benjamin, H.; Ben-David, M.; Cohen, L.; Dov, A.; Dromi, N.; Elyakim, E.; Yerushalmi, N.; Zion, O.; et al. Discovery of microRNAs and other small RNAs in solid tumors. Nucleic Acids Res. 2010, 38, 6234-6246.
197. Gupta, S.K.; Bang, C.; Thum, T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ. Cardiovasc. Genet. 2010, 3, 484-488.
198. Buckland, J. Biomarkers: microRNAs under the spotlight in inflammatory arthritis. Nat. Rev. Rheumatol. 2010, 6, 436.
199. D'Alessandra, Y.; Devanna, P.; Limana, F.; Straino, S.; Di Carlo, A.; Brambilla, P.G.; Rubino, M.; Carena, M.C.; Spazzafumo, L.; De Simone, M.; et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart J. 2010, doi:10.1093/eurheartj/ehq167.
200. Alevizos, I.; Illei, G.G. MicroRNAs as biomarkers in rheumatic diseases. Nat. Rev. Rheumatol. 2010, 6, 391-398.
201. De Smaele, E.; Ferretti, E.; Gulino, A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res. 2010, 1338, 100-111.
202. Santos-Reboucas, C.B.; Pimentel, M.M. MicroRNAs: Macro challenges on understanding human biological functions and neurological diseases. Curr. Mol. Med. 2010, 10, 692-704.
203. Jeyaseelan, K.; Lim, K.Y.; Armugam, A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke 2008, 39, 959-966.
204. Tan, K.S.; Armugam, A.; Sepramaniam, S.; Lim, K.Y.; Setyowati, K.D.; Wang, C.W.; Jeyaseelan, K. Expression profile of MicroRNAs in young stroke patients. PLoS one 2009, 4, e7689.
205. Chen, C.; Skog, J.; Hsu, C.H.; Lessard, R.T.; Balaj, L.; Wurdinger, T.; Carter, B.S.; Breakefield, X.O.; Toner, M.; Irimia, D. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab. Chip 2010, 10, 505-511.
206. Bader, A.G.; Brown, D.; Winkler, M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70, 7027-7030.
207. Li, Y.; He, C.; Jin, P. Emergence of chemical biology approaches to the RNAi/miRNA pathway. Chem. Biol. 2010, 17, 584-589.
208. Wang, M.; Xie, H.; Stellpflug, W.; Rajaram, V.; de Fatima Bonaldo, M.; Goldman, S.; Tomita, T.; Soares, M.B. BTECH: A platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors. Neuroinformatics 2011, 9, 59-67.